Comparative Pharmacology
Head-to-head clinical analysis: HEXABRIX versus ISOVUE 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXABRIX versus ISOVUE 300.
HEXABRIX vs ISOVUE-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.
Intravenous: 0.3-0.6 mL/kg (maximum 100 mL) for urography; 40-80 mL for CT enhancement.
Intravenous: 50-150 mL (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 mL depending on procedure; intrathecal: 8-15 mL. Maximum total iodine dose: 300 mg iodine/kg.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD)
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 mL/min), the half-life can be prolonged up to 20–40 hours, requiring dose adjustment.
Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1%
Primarily renal (glomerular filtration), with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% is excreted via bile/fecal route.
Category C
Category C
Contrast Media
Contrast Media